CHMP recommends SonoVue reinstatement

Europe's Committee for Human Medicinal Products (CHMP) has recommended reinstating the echocardiography indication for Bracco's SonoVue ultrasound contrast agent.

SonoVue's echocardiography indication was temporarily suspended on May 21 as a precautionary measure in agreement with the European Agency for the Evaluation of Medicinal Products (EMEA). CHMP recommended that the reinstatement of SonoVue be accompanied by an extension of contraindications to patients with recent acute coronary symptoms or clinically unstable ischemic cardiac disease, according to Bracco.

By staff writers
August 5, 2004

Related Reading

Bracco clarifies SonoVue restrictions, May 24, 2004

EMEA restricts use of SonoVue, May 20, 2004

Bracco sets up new facility in Italy, May 4, 2004

Bracco forms Chinese joint venture, April 5, 2004

Bracco adds Christus Health, April 5, 2004

Copyright © 2004

Page 1 of 509
Next Page